Compare Illumina, Inc. (ILMN) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Roundhill Magnificent Seven ETF — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Roundhill Magnificent Seven ETF trades at $67.05. The key difference: Illumina, Inc. is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | MAGS | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $194.33 | $70.94 |
52-Week Low | $91.00 | $55.39 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.93, showing minimal daily movement with a neutral technical signal. It holds an equal-weight basket of seven mega-cap tech stocks, benefiting from AI-driven market trends but facing concentration risks. Recent news highlights AI spending shifts and broadening market gains beyond chipmakers.
The ETF's outlook hinges on AI adoption and hyperscaler performance, with potential from compressed valuations, but risks include overconcentration and high expectations. Institutional interest remains strong, though analyst views are mixed amid sector rotation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
